Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a Healthcare company (Biotechnology) with a market capitalization of $3.5B. The Maz Rating grades it against the other companies in its sector.
Amylyx Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.52, Amylyx Pharmaceuticals, Inc. trades at 4.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -41.5%, return on invested capital of -23.2% and a free cash flow yield of -3.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 26.81. Over the past 52 weeks the share price ranged from $10.83 to $41.14, with a beta of -0.20.
Amylyx Pharmaceuticals, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.2% / 30% · Interest income / Revenue 418300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.2% / 33% · Receivables / Mkt Cap (36m) 0.08% / 49% · Interest income / Revenue 418300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.2% / 33.33% · Receivables / Mkt Cap (24m) 0.08% / 33.33% · Interest income / Revenue 418300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.55% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.3% / 33.33% · Receivables / Avg Assets (4Q) 0.18% / 33.33% · Interest income / Revenue 418300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.6% / 33.33% · (Cash+Recv) / Total Assets 98.0% / 33.33% · Interest income / Revenue 418300000.0% / 5% | Fail |
No. As of September 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Amylyx Pharmaceuticals, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 418300000.0% of each dividend: Amylyx Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.